There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation which composition comprises a glitazone such as pioglitazone or rosiglitazone and one or more pharmaceutically acceptable carriers and/or excipients and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and a kit.

There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation which composition comprises a glitazone such as pioglitazone or rosiglitazone and one or more pharmaceutically acceptable carriers and/or excipients and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.

There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation which composition comprises a glitazone such as pioglitazone or rosiglitazone and one or more pharmaceutically acceptable carriers and/or excipients and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and a kit.

There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation which composition comprises a glitazone such as pioglitazone or rosiglitazone and one or more pharmaceutically acceptable carriers and/or excipients and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.